About Octamer
Octamer is a company based in Grafelfing (Germany) founded in 2018 was acquired by Volition in December 2019. Octamer operates in a competitive market with competitors including Neogen, Parse Biosciences, Qiagen, Biofidelity and Fluent BioSciences, among others.
- Headquarter Grafelfing, Germany
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website octamer.de
- Social LinkedIn
- Acquired by Volition (Dec 2019)
Investors in Octamer
Octamer has secured backing from 1 investor. Prominent investors backing the company include Volition.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Volition is focused on developing epigenetic diagnostic solutions. | 1995 | volition.com | Gembloux, Belgium |
Investor details for Octamer
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Octamer
2 dated milestones of Octamer across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Octamer is founded.
- Exit Acquired by Volition.
Competitors of Octamer
Octamer operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Neogen, Parse Biosciences, Qiagen, Biofidelity and Fluent BioSciences, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| neogen.com | 1982 | Lansing, United States | $700,000 | 2,640 | Manufacturer of products in the areas of veterinary diagnostics, life sciences, DNA testing, and drug testing | |
| parsebiosciences.com | 2018 | Seattle, United States | $100.26M | – | RNA-sequencing transcriptome kits for health data analysis are developed. | |
| qiagen.com | 1984 | Hilden, Germany | – | 104 | Products and reagents for molecular diagnostic assays are supplied. | |
| biofidelity.com | 2002 | Cambridge, United Kingdom | $59.91M | 28 | Molecular diagnostic assays are developed for target DNA sequence detection. | |
| fluentbio.com | 2018 | Watertown, United States | $19M | – | Proprietary reagents for single-cell genetic analysis are developed. | |
| rarecyte.com | 2009 | Seattle, United States | $114.33M | 54 | Developer of technologies for the analysis of rare and single cells in the blood | |
| sebia.com | 1967 | Evry Courcouronnes, France | – | – | Electrophoresis-based in vitro diagnostics products are developed and provided. | |
| nuprobe.com | 2016 | George Town, Cayman Islands | $61M | – | Sensitive multiplex platforms for QPCR are developed using toehold probes. | |
| raindancetech.com | 2004 | Billerica, United States | $111.66M | 105 | Developer of nucleic acid detection and quantification systems |
Detailed competitors of Octamer
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Octamer
Complete news archive for Octamer
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Octamer
10 companies that operate in the same segment as Octamer (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Octamer
Octamer was founded in 2018.
Octamer is headquartered in Grafelfing, Germany. It is registered at Grafelfing, Bavaria, Germany.
Octamer was founded in 2018 in Grafelfing, Germany, where operations center on the biotechnology sector. Screening substrates tailored for epigenetics research are offered, encompassing histones, nucleosomes, histone octamers, and DNA templates. Nucleosomes serve as control reagents in applications such as mode of action studies, biophysical profiling, and structural biology. The focus remains on supporting research needs in this specialized field.
Octamer's top competitors include Neogen, Qiagen and Parse Biosciences.
Octamer has 1 investor. Key investors include Volition.
Yes. Octamer was acquired by Volition in December 2019.